Axonics, Inc. (NASDAQ:AXNX) Position Lessened by NBC Securities Inc.

NBC Securities Inc. lowered its position in Axonics, Inc. (NASDAQ:AXNX) by 25.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 499 shares of the company’s stock after selling 172 shares during the quarter. NBC Securities Inc.’s holdings in Axonics were worth $34,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Axonics during the 2nd quarter valued at about $15,080,000. Maven Securities LTD bought a new stake in Axonics in the second quarter worth approximately $1,008,000. Granite Bay Wealth Management LLC bought a new stake in Axonics in the second quarter worth approximately $1,698,000. Algert Global LLC increased its stake in shares of Axonics by 26.0% during the 2nd quarter. Algert Global LLC now owns 33,847 shares of the company’s stock worth $2,276,000 after purchasing an additional 6,978 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new position in shares of Axonics during the 2nd quarter worth $1,208,000. 99.48% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reissued a “hold” rating on shares of Axonics in a research report on Monday, August 5th. Eight equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $69.57.

Axonics Trading Down 0.1 %

NASDAQ:AXNX opened at $70.24 on Monday. The firm has a market capitalization of $3.58 billion, a PE ratio of -219.50 and a beta of 0.82. Axonics, Inc. has a 1 year low of $48.30 and a 1 year high of $70.53. The firm’s fifty day simple moving average is $69.28 and its 200 day simple moving average is $68.14.

Axonics (NASDAQ:AXNX) last posted its quarterly earnings data on Thursday, August 1st. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $0.03. Axonics had a negative return on equity of 0.27% and a negative net margin of 0.42%. The business had revenue of $114.57 million for the quarter, compared to analyst estimates of $112.83 million. During the same period in the previous year, the company posted ($0.15) earnings per share. The firm’s revenue for the quarter was up 23.3% on a year-over-year basis. As a group, analysts anticipate that Axonics, Inc. will post 0.24 EPS for the current fiscal year.

Insider Transactions at Axonics

In related news, CFO Kari Leigh Keese sold 2,961 shares of the business’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $69.41, for a total transaction of $205,523.01. Following the transaction, the chief financial officer now owns 40,362 shares of the company’s stock, valued at approximately $2,801,526.42. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 1.85% of the company’s stock.

Axonics Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.